Cargando…
Management of hemolytic-uremic syndrome in children
Acute renal failure associated with a fulminant, life-threatening systemic disease is rare in previously healthy young children; however, when it occurs, the most common cause is hemolytic-uremic syndrome (HUS). In most cases (90%), this abrupt and devastating illness is a result of ingestion of foo...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062558/ https://www.ncbi.nlm.nih.gov/pubmed/24966691 http://dx.doi.org/10.2147/IJNRD.S41837 |
_version_ | 1782321674796924928 |
---|---|
author | Grisaru, Silviu |
author_facet | Grisaru, Silviu |
author_sort | Grisaru, Silviu |
collection | PubMed |
description | Acute renal failure associated with a fulminant, life-threatening systemic disease is rare in previously healthy young children; however, when it occurs, the most common cause is hemolytic-uremic syndrome (HUS). In most cases (90%), this abrupt and devastating illness is a result of ingestion of food or drink contaminated with pathogens that produce very potent toxins. Currently, there are no proven treatment options that can directly inactivate the toxin or effectively interfere with the cascade of destructive events triggered by the toxin once it gains access to the bloodstream and binds its receptor. However, HUS is self-limited, and effective supportive management during the acute phase is proven to be a life saver for children affected by HUS. A minority of childhood HUS cases, approximately 5%, are caused by various genetic mutations causing uncontrolled activation of the complement system. These children, who used to have a poor prognosis leading to end-stage renal disease, now have access to exciting new treatment options that can preserve kidney function and avoid disease recurrences. This review provides a summary of the current knowledge on the epidemiology, pathophysiology, and clinical presentation of childhood HUS, focusing on a practical approach to best management measures. |
format | Online Article Text |
id | pubmed-4062558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40625582014-06-25 Management of hemolytic-uremic syndrome in children Grisaru, Silviu Int J Nephrol Renovasc Dis Review Acute renal failure associated with a fulminant, life-threatening systemic disease is rare in previously healthy young children; however, when it occurs, the most common cause is hemolytic-uremic syndrome (HUS). In most cases (90%), this abrupt and devastating illness is a result of ingestion of food or drink contaminated with pathogens that produce very potent toxins. Currently, there are no proven treatment options that can directly inactivate the toxin or effectively interfere with the cascade of destructive events triggered by the toxin once it gains access to the bloodstream and binds its receptor. However, HUS is self-limited, and effective supportive management during the acute phase is proven to be a life saver for children affected by HUS. A minority of childhood HUS cases, approximately 5%, are caused by various genetic mutations causing uncontrolled activation of the complement system. These children, who used to have a poor prognosis leading to end-stage renal disease, now have access to exciting new treatment options that can preserve kidney function and avoid disease recurrences. This review provides a summary of the current knowledge on the epidemiology, pathophysiology, and clinical presentation of childhood HUS, focusing on a practical approach to best management measures. Dove Medical Press 2014-06-12 /pmc/articles/PMC4062558/ /pubmed/24966691 http://dx.doi.org/10.2147/IJNRD.S41837 Text en © 2014 Grisaru. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Grisaru, Silviu Management of hemolytic-uremic syndrome in children |
title | Management of hemolytic-uremic syndrome in children |
title_full | Management of hemolytic-uremic syndrome in children |
title_fullStr | Management of hemolytic-uremic syndrome in children |
title_full_unstemmed | Management of hemolytic-uremic syndrome in children |
title_short | Management of hemolytic-uremic syndrome in children |
title_sort | management of hemolytic-uremic syndrome in children |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062558/ https://www.ncbi.nlm.nih.gov/pubmed/24966691 http://dx.doi.org/10.2147/IJNRD.S41837 |
work_keys_str_mv | AT grisarusilviu managementofhemolyticuremicsyndromeinchildren |